Please note: The information displayed on this page might be outdated.
Kiadis Pharma N.V.: NK-cell platform administered as adjunct I-O on top of HSCT. High-dose potent NK cells expanded/activated w patented PM21 nanoparticles. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, US - New England
Clinical Stage
Phase III, Phase l or ll, Pre-Clinical Stage
Disease Space
Hematology, Immunotherapy, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
Boston
Boston, MA
United States

Company Participants at Solebury Trout KOL Day

  • Arthur Lahr, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Kiadis Pharma NV

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
BNP Paribas Asset Management Belgium SA 0.41 119,740 0.00 Funds 2020-05-29
FundQuest Advisor 0.12 41,691 0.00 Funds 2019-09-30
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.